ABECMA

This brand name is authorized in United States. It is also authorized in Austria, Canada, Croatia, Cyprus, Estonia, France, Ireland, Italy, Lithuania, Poland.

Active ingredients

The drug ABECMA contains one active pharmaceutical ingredient (API):

1	Idecabtagene vicleucel UNII 8PX1X7UG4D - IDECABTAGENE VICLEUCEL
	Idecabtagene vicleucel is a chimeric antigen receptor (CAR)-positive T cell therapy targeting B-cell maturation antigen (BCMA), which is expressed on the surface of normal and malignant plasma cells. The CAR construct includes an anti-BCMA scFv-targeting domain for antigen specificity, a transmembrane domain, a CD3-zeta T cell activation domain, and a 4-1BB costimulatory domain. Antigen-specific activation of idecabtagene vicleucel results in CAR-positive T cell proliferation, cytokine secretion and subsequent cytolytic killing of BCMA-expressing cells.
	Read more about Idecabtagene vicleucel

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ABECMA Dispersion for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XL07		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XL Antineoplastic cell and gene therapy
Discover more medicines within L01XL07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02516233
EE	Ravimiamet	1860140
FR	Base de données publique des médicaments	65329132
IT	Agenzia del Farmaco	049604010
LT	Valstybinė vaistų kontrolės tarnyba	1093238
PL	Rejestru Produktów Leczniczych	100457776
US	FDA, National Drug Code	59572-515